X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for rare diseases of the immune system. Its product XOLREMDI is an orally administered small-molecule selective antagonist of the chemokine receptor CXCR4 and is in a phase 3 clinical trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company has license agreements with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau; with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and with Genzyme Corporation for the CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic, and diagnostic uses. X4 Pharmaceuticals is headquartered in Boston, Massachusetts.

XFOR▲

X4 Pharmaceuticals Appoints Kelly Gold to Board of Directors

X4 Pharmaceuticals has appointed Kelly Gold to its Board of Directors effective July 1, 2026. Ms. Gold will serve as an independent director and member of the Audit Committee. She is currently the Chief Financial Officer at CAMP4 Therapeutics and brings financial leadership, capital markets expertise, and a scientific background to the board. The company stated that her experience as a public company CFO and her understanding of the biotech landscape will support X4 as it advances mavorixafor toward potential approval and commercialization.

XFOR ▲

GlobeNewswire·79dRead more →